Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
Upcoming NextGen Omics Series Webinars
Simultaneous, High-Yield Extraction of DNA and RNA from FFPE Tissue
Tuesday 14 September 2021 | 11:00 - 12:00 EDT (UTC-4)
Lewis Marshall, Ph.D. – VP of R&D, Purigen Biosystems
Sankar Mohan, Ph.D. – Director of Operations, Canopy Biosciences
FFPE tissue and samples with a low abundance of high-quality nucleic acid represent a bottleneck in sample preparation workflows. Researchers and clinicians working with these samples often resort to labor-intensive and potentially biased methods in order to isolate sufficient material for downstream analyses.
Purigen Biosystems has recently launched the revolutionary Ionic® Purification System and Kits to recover more RNA and DNA from FFPE samples with a simple, automated approach using isotachophoresis. The new Ionic® FFPE Complete Purification Kit combines the benefits of the RNA and DNA extraction kits for FFPE samples into a single workflow with minimal hands-on time.
Purigen’s core technology, isotachophoresis, separates and concentrates charged molecules in solution solely based on their electrophoretic mobility. Biological samples are gently lysed and added to the Purigen Ionic® Fluidic Chip. An electric field is then applied to the chip and the nucleic acid is isolated in its natural, native form. The nucleic acid is not denatured or dehydrated, and there’s no binding to, or stripping from, fixed surfaces. The result is a higher yield of pure nucleic acid that is less fragmented and free from bead or wash buffer contamination.
In this webinar, we share results from downstream molecular analyses of RNA and DNA purified from FFPE samples in a single workflow using the Ionic® Purification System.
Attendees will learn about Purigen Biosystems’ innovative approach to automated nucleic acid purification and how the Ionic® Purification System can be used to extract more DNA and RNA from challenging FFPE samples with more reliability and less effort by comparison to conventional extraction methods.
Lewis Marshall – Lewis Marshall is a scientific researcher with a focus on electrophoresis and Isotachophoresis. He received his Ph.D. in Chemical Engineering from Stanford University in 2013. As the VP of R&D at Purigen Biosystems, Lewis has led the development of automated systems and fluidic devices to purify nucleic acids. He currently leads a team responsible for the development of products to purify nucleic acid from FFPE tissue.
Sanker Mohan – Dr. Sankar Mohan is the Director of Operations at Canopy Biosciences, a Bruker company. Dr. Mohan received his Ph.D. from Hiroshima University, Japan, and subsequently completed his post-doctoral training in the Department of Radiation Oncology at Albert Einstein College of Medicine, New York. He has over 20 years of experience in field of Molecular Biology. He has published several articles in peer-reviewed journals and has presented his work at national and international conferences.
Single cell genome engineering: Combining the power of CRISPR with FluidFM®
Tuesday 28 September 2021 | 09:00 - 10:00 EDT (UTC -4)
Dr. Tobias Beyer, CSO / Senior Cell Biologist, Cytosurge AG
In the 21st century, the genomic revolution is dawning and with it the way biomedical research is performed. Whole genome sequencing is affordable and therefore, the causes of common genetic diseases become known. With the advent of the CRISPR/Cas system, cell line engineering to introduce precise modifications into genomes is taking the center stage in modern biomedical research. However, to turn this genomic information and the ability to modify genomes into curing diseases, several obstacles must be cleared. Cell line engineering is still hampered by inefficient delivery of genome editing entities, the danger of mutations in unrelated genomic regions and low efficiencies for precise editing by homologous recombination.
To address these hurdles, we combine CRISPR based genome engineering with our FluidFM® technology. By injecting the genome editing entities directly into the nucleus of a target cell, we circumvent the delivery barrier. Further, the controlled delivery of CRISPR ribonucleic protein complexes to the nucleus of the target cell will minimize the probability of off-target editing and enhance homologous recombination by co-injecting HDR templates. In addition, our single cell approach avoids the tedious selection process and reduces the material costs to a minimum.
In summary, using FluidFM technology to perform single cell genome engineering will improve the quality and the speed, and reduces the costs of cell line development projects in academic and industrial biomedical research.
- What is FluidFM® and how can it be applied to cell line engineering
- True single cell genome engineering: the power of the bottom-up approach
- High quality monoclonal cell lines by reducing off-target editing and avoiding the tedious selection process
- Cut the cost by using minimal amounts of reagents and cells
- Speed up the process by staring with a single cell
Dr. Tobias Beyer obtained his PhD in Cell Biology at ETH Zurich. After a postdoctoral fellowship at the LTRI in Toronto, he joined ETH Zurich as junior group leader (Groups of Prof. Wutz and Prof. Corn). Here, he combined his expertise in cell biology, cell signaling, and embryonic stem cells with genome engineering using the CRISPR/Cas9 technology. At Cytosurge, Dr. Beyer identifies and develops applications for the FluidFM OMNIUM.